Erinne R. Dabkowski

Array ( [id] => 13490175 [patent_doc_number] => 20180296630 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-18 [patent_title] => METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS [patent_app_type] => utility [patent_app_number] => 15/825298 [patent_app_country] => US [patent_app_date] => 2017-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38100 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15825298 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15254115 [patent_doc_number] => 20190375791 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-12 [patent_title] => NEW D-CONFIGURED CATESLYTIN PEPTIDE [patent_app_type] => utility [patent_app_number] => 16/462967 [patent_app_country] => US [patent_app_date] => 2017-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23038 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16462967 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12724489 [patent_doc_number] => 20180133330 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-17 [patent_title] => CONJUGATE INCLUDING PEPTIDE MOLECULE CAPABLE OF SELF-ASSEMBLY IN CELL ORGANELLE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER INCLUDING CONJUGATE [patent_app_type] => utility [patent_app_number] => 15/813646 [patent_app_country] => US [patent_app_date] => 2017-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10638 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15813646 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16620043 [patent_doc_number] => 20210038696 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => RECTAL INSULIN FOR TREATMENT OF INFLAMMATORY BOWEL DISEASES [patent_app_type] => utility [patent_app_number] => 16/348389 [patent_app_country] => US [patent_app_date] => 2017-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16065 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16348389 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16156519 [patent_doc_number] => 20200216492 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-09 [patent_title] => USE OF C-TERMINALLY EXTENDED PEPTIDES TO DISRUPT INHIBITOR NK CELL RECEPTOR INTERACTIONS WITH MHC I [patent_app_type] => utility [patent_app_number] => 16/348839 [patent_app_country] => US [patent_app_date] => 2017-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23536 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -73 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16348839 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14749313 [patent_doc_number] => 20190257830 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => DETECTION AND TREATMENT OF DEMYELINATING DISEASES [patent_app_type] => utility [patent_app_number] => 16/346478 [patent_app_country] => US [patent_app_date] => 2017-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10598 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16346478 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17821517 [patent_doc_number] => 11426441 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-30 [patent_title] => Composition comprising protein phosphatase 1 inhibitory peptide for treating vascular diseases [patent_app_type] => utility [patent_app_number] => 16/344467 [patent_app_country] => US [patent_app_date] => 2017-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 53 [patent_no_of_words] => 14129 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16344467 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12680869 [patent_doc_number] => 20180118789 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => CHIMERIC MELANOCORTIN LIGANDS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/786005 [patent_app_country] => US [patent_app_date] => 2017-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17763 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 240 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15786005 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12177447 [patent_doc_number] => 20180036383 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-02-08 [patent_title] => 'TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL DEGENERATIVE DISORDER' [patent_app_type] => utility [patent_app_number] => 15/784424 [patent_app_country] => US [patent_app_date] => 2017-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11106 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15784424 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15408005 [patent_doc_number] => 20200024324 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-23 [patent_title] => NEW PDL2 COMPOUNDS [patent_app_type] => utility [patent_app_number] => 16/344445 [patent_app_country] => US [patent_app_date] => 2017-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14079 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16344445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15432461 [patent_doc_number] => 20200030413 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF KIDNEY CANCER [patent_app_type] => utility [patent_app_number] => 16/339931 [patent_app_country] => US [patent_app_date] => 2017-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8693 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16339931 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15432461 [patent_doc_number] => 20200030413 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF KIDNEY CANCER [patent_app_type] => utility [patent_app_number] => 16/339931 [patent_app_country] => US [patent_app_date] => 2017-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8693 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16339931 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13368969 [patent_doc_number] => 20180236025 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-23 [patent_title] => METHODS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE [patent_app_type] => utility [patent_app_number] => 15/723259 [patent_app_country] => US [patent_app_date] => 2017-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15196 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15723259 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16555761 [patent_doc_number] => 20210000909 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => PEPTIDE COMPOSITION FOR TREATING EXCITATORY NEUROTOXICITY RELATED INJURIES [patent_app_type] => utility [patent_app_number] => 16/652323 [patent_app_country] => US [patent_app_date] => 2017-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13423 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16652323 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13342801 [patent_doc_number] => 20180222940 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-09 [patent_title] => MU OPIOID RECEPTOR AGONIST ANALOGS OF THE ENDOMORPHINS [patent_app_type] => utility [patent_app_number] => 15/704730 [patent_app_country] => US [patent_app_date] => 2017-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10892 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15704730 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12580773 [patent_doc_number] => 20180085420 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-29 [patent_title] => EZETIMIBE-ASSOCIATED APOA-I MIMETIC PEPTIDES SHOWING ENHANCED SYNERGISM [patent_app_type] => utility [patent_app_number] => 15/702435 [patent_app_country] => US [patent_app_date] => 2017-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29470 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15702435 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12769927 [patent_doc_number] => 20180148477 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-31 [patent_title] => NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 15/698407 [patent_app_country] => US [patent_app_date] => 2017-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52008 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15698407 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14581313 [patent_doc_number] => 20190218265 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => Novel Ligand and Use Thereof [patent_app_type] => utility [patent_app_number] => 16/328058 [patent_app_country] => US [patent_app_date] => 2017-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10882 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16328058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17095316 [patent_doc_number] => 20210283107 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-16 [patent_title] => Methods to Expand the Spectrum of Gram-Positive Antibiotics [patent_app_type] => utility [patent_app_number] => 16/325602 [patent_app_country] => US [patent_app_date] => 2017-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8442 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16325602 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12150141 [patent_doc_number] => 20180021405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-25 [patent_title] => 'NUTRITIONAL APPROACH TO THE CONTROL OF ANEMIA, DIABETES AND OTHER DISEASES OR CONDITIONS AND PREVENTION OF ASSOCIATED COMORBID STATES WITH THE USE OF ERGOTHIONEINE' [patent_app_type] => utility [patent_app_number] => 15/672941 [patent_app_country] => US [patent_app_date] => 2017-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 16765 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15672941 [rel_patent_id] =>[rel_patent_doc_number] =>)